Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 14/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.39 |
| ▸ | DLK1 | P80370 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19221771 | 1.00 | MAP3K12 (0.44) | MAP3K12MTORPIK3CAMAP3K13DLK1 | |
| SCHEMBL15399356 | 1.00 | MAP3K12 (0.44) | MAP3K12MTORPIK3CAMAP3K13DLK1 | |
| SCHEMBL25889731 | 0.83 | MAP3K12 (0.39) | MAP3K12MTORPIK3CAMAP3K13DLK1 | |
| SCHEMBL30206581 | 0.83 | MAP3K12 (0.39) | MAP3K12MTORPIK3CAMAP3K13DLK1 | |
| SCHEMBL12082429 | 0.83 | SOS1 (0.39) | MAP3K12MTORPIK3CASOS1PRKDC | |
| SCHEMBL30206213 | 0.83 | MAP3K12 (0.39) | MAP3K12MTORPIK3CAMAP3K13DLK1 | |
| SCHEMBL25889732 | 0.83 | MAP3K12 (0.39) | MAP3K12MTORPIK3CAMAP3K13DLK1 | |
| SCHEMBL21256819 | 0.83 | SOS1 (0.39) | MAP3K12MTORPIK3CASOS1PRKDC | |
| SCHEMBL21256815 | 0.83 | SOS1 (0.39) | MAP3K12MTORPIK3CASOS1PRKDC | |
| SCHEMBL18436556 | 0.82 | PRKDC (0.45) | MAP3K12MTORPIK3CAMAP3K13SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683909-A2 | ATM KINASE INHIBITORS | Eberhard Karls Universität Tübingen (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-20260015328-A1 | ATM KINASE INHIBITORS | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2026-01-15 | — | — | US | disclosed |
| WO-2024194460-A2 | ATM KINASE INHIBITORS | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2024-09-26 | — | — | WO | disclosed |
| EP-4434972-A1 | ATM KINASE INHIBITORS | Eberhard-Karls-Universität Tübingen (DE) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024107393-A1 | TRICYCLIC COMPOUNDS | SCHRÖDINGER, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-10766902-B2 | Wee-1 inhibiting pyrazolopyrimidinone compounds | ALMAC DISCOVERY LIMITED (GB) | 2020-09-08 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20190248795-A1 | WEE-1 INHIBITING PYRAZOLOPYRIMIDINONE COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2019-08-15 | — | — | US | disclosed |
| EP-3484887-A1 | WEE-1 INHIBITING PYRAZOLOPYRIMIDINONE COMPOUNDS | Almac Discovery Limited (GB) | 2019-05-22 | — | — | EP | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| WO-2018011569-A1 | WEE-1 INHIBITING PYRAZOLOPYRIMIDINONE COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2018-01-18 | — | — | WO | disclosed |
| EP-2867238-B1 | PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2017-08-09 | — | — | EP | disclosed |
| EP-2867238-B1 | PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2017-08-09 | — | — | EP | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| EP-2867238-A1 | PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF | YM BioSciences Australia Pty Ltd (AU) | 2015-05-06 | — | — | EP | disclosed |
| US-8809359-B2 | Phenyl amino pyrimidine bicyclic compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (US) | 2014-08-19 | — | — | US | disclosed |
| WO-2014000032-A1 | PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2014-01-03 | — | — | WO | disclosed |
| US-20140005161-A1 | PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY LTD (US) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAP3K12 79/4885MTOR 327/4885PIK3CA 1016/4885 |
| US-20190248795-A1 | WEE-1 INHIBITING PYRAZOLOPYRIMIDINONE COMPOUNDS | WEE1, WEE2, PPME1 | MAP3K12 57/4885MTOR 505/4885PIK3CA 191/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAP3K12 90/4885MTOR 291/4885PIK3CA 410/4885 |
| US-10766902-B2 | Wee-1 inhibiting pyrazolopyrimidinone compounds | WEE1, WEE2, PPME1 | MAP3K12 50/4885MTOR 368/4885PIK3CA 181/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAP3K12 79/4885MTOR 327/4885PIK3CA 1016/4885 |
| US-20140005161-A1 | PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | MAP3K12 66/4885MTOR 257/4885PIK3CA 318/4885 |
| US-20260015328-A1 | ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | MAP3K12 162/4885MTOR 300/4885PIK3CA 326/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MAP3K12 67/4885MTOR 293/4885PIK3CA 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.